{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:42:04Z","timestamp":1789519324492,"version":"build-2803163510"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1097\/cad.0b013e3283287c20","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T10:08:48Z","timestamp":1242900528000},"page":"346-354","source":"Crossref","is-referenced-by-count":60,"title":["Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777"],"prefix":"10.1097","volume":"20","author":[{"given":"Pierre","family":"Beauparlant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"B\u00e9dard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Bernier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Goulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel-Olivier","family":"Gratton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Lavoie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Roulston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9milie","family":"Turcotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210203","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1016\/j.bmcl.2005.03.064","article-title":"EB1627: a soluble prodrug of the potent anticancer cyanoguanidine CHS828","volume":"15","author":"Binderup","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"key":"R2-5-20210203","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1016\/S0960-894X(97)10152-4","article-title":"Novel cyanoguanidines with potent oral antitumor activity","volume":"7","author":"Schou","year":"1997","journal-title":"Bioorg Med Chem Lett"},{"key":"R3-5-20210203","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.bbrc.2008.01.019","article-title":"Anticancer agent CHS-828 inhibits cellular synthesis of NAD","volume":"367","author":"Olesen","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"R4-5-20210203","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1517\/14728222.11.5.695","article-title":"Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery","volume":"11","author":"Khan","year":"2007","journal-title":"Expert Opin Ther Targets"},{"key":"R5-5-20210203","first-page":"5751","article-title":"CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo","volume":"59","author":"Hjarnaa","year":"1999","journal-title":"Cancer Res"},{"key":"R6-5-20210203","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00001813-200401000-00010","article-title":"Cytotoxic effect in vivo and in vitro of CHS 828 on human myeloma cell lines","volume":"15","author":"Hovstadius","year":"2004","journal-title":"Anticancer Drugs"},{"key":"R7-5-20210203","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/00001813-200111000-00005","article-title":"Activity of CHS 828 in primary cultures of human hematological and solid tumors in vitro","volume":"12","author":"\u00c4leskog","year":"2001","journal-title":"Anticancer Drugs"},{"key":"R8-5-20210203","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1203\/00006450-200205000-00011","article-title":"CHS 828 inhibits neuroblastoma growth in mice alone and in combination with antiangiogenic drugs","volume":"51","author":"Svensson","year":"2002","journal-title":"Pediatr Res"},{"key":"R9-5-20210203","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000091754","article-title":"Antitumoural effects of the pyridyl cyanoguanidine CHS 828 on three different types of neuroendocrine tumours xenografted to nude mice","volume":"82","author":"Johanson","year":"2005","journal-title":"Neuroendocrinology"},{"key":"R10-5-20210203","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.ejca.2004.12.023","article-title":"Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG\/EORTC study","volume":"41","author":"Ravaud","year":"2005","journal-title":"Eur J Cancer"},{"key":"R11-5-20210203","first-page":"2843","article-title":"A phase I study of CHS 828 in patients with solid tumor malignancy","volume":"8","author":"Hovstadius","year":"2002","journal-title":"Clin Cancer Res"},{"key":"R12-5-20210203","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/jps.2600570506","article-title":"4-acetamidophenyl 2,2,2-trichlorethyl carbonate synthesis, physical properties, and in vitro hydrolysis","volume":"57","author":"Swintosky","year":"1968","journal-title":"J Pharm Sci"},{"key":"R13-5-20210203","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/jps.2600570511","article-title":"Acetaminophen prodrugs. II. Effect of structure and enzyme source on enzymatic and nonenzymatic hydrolysis of carbonate esters","volume":"57","author":"Dittert","year":"1968","journal-title":"J Pharm Sci"},{"key":"R14-5-20210203","doi-asserted-by":"crossref","first-page":"6700","DOI":"10.1158\/0008-5472.CAN-03-2942","article-title":"SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 2: efficacy evaluations","volume":"64","author":"Alley","year":"2004","journal-title":"Cancer Res"},{"key":"R15-5-20210203","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/S0022-3565(24)29239-9","article-title":"Model for time dependency of cytotoxic effect of CHS 828 in vitro suggests two different mechanisms of action","volume":"299","author":"Hassan","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"R16-5-20210203","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0895-7061(02)03196-5","article-title":"Hemodynamic effects of nicotinic acid infusion in normotensive and hypertensive subjects","volume":"16","author":"Gadegbeku","year":"2003","journal-title":"Am J Hypertens"},{"key":"R17-5-20210203","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1055\/s-2007-1003351","article-title":"Effect of nicotinic acid on plasma glucose concentration in normal individuals","volume":"24","author":"Landau","year":"1992","journal-title":"Horm Metab Res"},{"key":"R18-5-20210203","doi-asserted-by":"crossref","first-page":"385","DOI":"10.4161\/auto.5635","article-title":"NAD depletion by FK866 induces autophagy","volume":"4","author":"Billington","year":"2008","journal-title":"Autophagy"},{"key":"R19-5-20210203","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1074\/jbc.M706204200","article-title":"Characterization of NAD uptake in mammalian cells","volume":"283","author":"Billington","year":"2008","journal-title":"J Biol Chem"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CAD.0b013e3283287c20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T16:39:21Z","timestamp":1739119161000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001813-200906000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0b013e3283287c20","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}